Atherosclerosis
Volume 169, Issue 1 , Pages 113-120, July 2003

The safety and immunogenicity of a CETP vaccine in healthy adults

  • Michael H. Davidson

      Affiliations

    • Rush-Presbyterian-St. Luke's Medical Center, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-312-563-2011; fax: +1-312-563-4417
    • ,
  • Kevin Maki

      Affiliations

    • Rush-Presbyterian-St. Luke's Medical Center, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    • ,
  • Denise Umporowicz

      Affiliations

    • Rush-Presbyterian-St. Luke's Medical Center, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    • ,
  • Alistair Wheeler

      Affiliations

    • AVANT Immunotherapeutics, Inc., Needham, MA, USA
    • ,
  • Charles Rittershaus

      Affiliations

    • AVANT Immunotherapeutics, Inc., Needham, MA, USA
    • ,
  • Una Ryan

      Affiliations

    • AVANT Immunotherapeutics, Inc., Needham, MA, USA

Received 20 September 2002; received in revised form 20 February 2003; accepted 7 March 2003.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0021-9150(03)00137-0

doi:10.1016/S0021-9150(03)00137-0

Atherosclerosis
Volume 169, Issue 1 , Pages 113-120, July 2003

Article Tools